Website profile

Inside Precision Medicine

Inside Precision Medicine is the only global media brand covering the full spectrum of precision medicine, taking a wide lens approach while bringing into sharp focus the many complex and interconnected issues that constitute the field.

  • 619articles · 365d
  • 2+ day agolatest article
  • Oct 17, 2025earliest in window
  • 96%with images
  • 344avg words
articles per day
Categories
  • Health & Wellness 586
  • Medical 579
  • Health 489
  • Science & Technology 124
  • Science & Nature 37
  • STEM 18
  • Business & Industrial 8
  • Economy, Business & Finance 3

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Inside Precision Medicine
insideprecisionmedicine.com > topics > oncology > prostate-cancer-genomic-analysis-links-mutational-footprints-to-clinical-outcomes

Prostate Cancer Genomic Analysis Links Mutational Footprints to Clinical Outcomes

3+ day, 6+ hour ago   (318+ words) An analysis of nearly 1000 prostate tumor samples has revealed eight integrated mutational footprints (IMFs) that underpin the majority of genetic alterations found in prostate cancer genomes, some of which reflect clinical outcomes. Although prostate cancer has a high prevalence, the…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > oncology > targetable-kras-g12c-mutation-uncommon-in-genitourinary-cancers

Targetable KRAS G12C Mutation Uncommon in Genitourinary Cancers

3+ day, 10+ hour ago   (474+ words) A comprehensive genomic profiling study involving more than 13,000 patients has shown that targetable G12C mutations in the KRAS oncogene are rare in genitourinary cancers, potentially limiting the role of routine testing and targeted treatment in these malignancies. KRAS G12C accounts for approximately…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > oncology > how-cancer-causing-proteins-accumulate-may-shape-response-to-protacs

How Cancer-Causing Proteins Accumulate May Shape Response to PROTACs

1+ week, 3+ day ago   (763+ words) The genetic mechanism driving an oncogene could help determine whether a tumor responds to protein-degrading therapies, potentially providing a new consideration for selecting patients for this emerging class of cancer drugs. The results suggest that tumors in which an oncogene…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > precision-medicine > new-platform-turns-protein-loss-into-a-signal-for-drug-discovery

New Platform Turns Protein Loss Into a Signal for Drug Discovery

1+ week, 5+ day ago   (463+ words) Researchers have developed a new way to detect small decreases in proteins inside living cells, creating an amplified signal that could make it easier to discover drugs that eliminate disease-causing proteins. The approach, called ratiometric transcriptional activation (RTA), converts the…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > oncology > prostate-cancer-rewires-amino-acid-metabolism-to-drive-treatment-resistance

Prostate Cancer Rewires Amino Acid Metabolism to Drive Treatment Resistance

3+ week, 2+ day ago   (397+ words) Researchers at Weill Cornell Medicine have identified a previously unknown link between amino acid metabolism and prostate cancer’s resistance to hormone therapy. Published in Nature Metabolism, the preclinical study found that prostate cancer cells can hijack the metabolism of two…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > oncology > flt3-mutant-aml-study-reveals-ferroptosis-as-a-hidden-drug-vulnerability

FLT3-Mutant AML Study Reveals Ferroptosis as a Hidden Drug Vulnerability

1+ mon, 5+ day ago   (520+ words) FLT3 inhibitors have changed the treatment landscape for FLT3-mutant acute myeloid leukemia, but they have not solved the central problem of relapse. Responses to drugs such as gilteritinib can be clinically meaningful, yet resistance frequently emerges, leaving researchers looking for the…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > precision-medicine > protein-restriction-may-promote-healthy-aging-and-longevity

Protein Restriction May Promote Healthy Aging and Longevity

1+ mon, 1+ week ago   (437+ words) Advice on how much protein to eat should be tailored according to physical activity and lowering intake could be of benefit to many people, possibly even increasing their lifespans. A review of more than 350 research papers, in Cell Press Blue,…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > precision-medicine > solving-a-40-year-mystery-could-advance-treatments-for-neurodegenerative-diseases

Solving a 40-Year Mystery Could Advance Treatments for Neurodegenerative Diseases

1+ mon, 3+ week ago   (422+ words) A decades-long mystery surrounding one of the nervous system’s most important molecular machines has been solved, providing a structural blueprint that could accelerate the development of targeted therapies for several inherited neurodegenerative diseases. Although kinesin-1 was the first member of…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > precision-medicine > structural-biology-reveals-new-drug-targets-for-rare-neuromuscular-disease

Structural Biology Reveals New Drug Targets for Rare Neuromuscular Disease

2+ mon, 6+ day ago   (304+ words) The study, published in Nature, explains how disease-causing mutations alter the human acetylcholine receptor (AChR), the protein responsible for converting nerve signals into muscle contraction. The findings also provide a framework for developing precision medicines tailored to the specific mutation…...

Inside Precision Medicine
insideprecisionmedicine.com > topics > precision-medicine > bacterial-docking-domains-may-open-new-paths-to-next-generation-hdac-inhibitors

Bacterial 'Docking Domains' May Open New Paths to Next-Generation HDAC Inhibitors

2+ mon, 1+ week ago   (442+ words) Researchers have uncovered the molecular mechanism bacteria use to build a family of natural anticancer compounds, a discovery that could help scientists engineer improved versions of histone deacetylase (HDAC) inhibitors for cancer treatment. The study, published in Nature Communications, identifies…...